In a multicenter phase II study, lorlatinib has shown substantial overall and intracranial activity both in the first-line and subsequent treatment of patients with ALK-positive NSCLC (Solomon et al., 2018). This evidence concerns the gene ALK and non-small cell lung carcinoma.